p53 codon 72 polymorphism and human papillomavirus associated skin cancer

D. P. O'Connor, E. W. Kay, M. Leader, G. J. Atkins, G. M. Murphy, M. J E M F Mabruk

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Background/Aims-Non-melanoma skin cancers frequently harbour multiple human papillomavirus (HPV) types. A recent report suggests that a polymorphism of the p53 tumour suppressor gene that results in the substitution of a proline residue with an arginine residue at position 72 of the p53 protein might act as a risk factor in HPV associated malignancies. This study aimed to determine the following: (1) the relation between HPV infection and the development of cutaneous squamous cell carcinoma (SCC), and (2) whether there is a correlation between p53 codon 72 polymorphism and the development of SCC. Methods-Blood samples were taken from 55 patients with skin cancer (both renal transplant recipients and immunocompetent patients with skin cancer) and 115 ethnically matched volunteers. A polymerase chain reaction based assay was used to determine p53 codon 72 genotypes. In addition, 49 benign and malignant lesions from 34 of the patients with skin cancer and 20 normal human skin samples from 20 of the control volunteers were examined for HPV. Results-The proportions of p53 codon 72 genotypes found were 78% arginine homozygous, 2% proline homozygous, and 20% heterozygous among patients with skin cancer and 79% arginine homozygous, 3.5% proline homozygous, and 17.5% heterozygous among the control population. Statistical analysis showed no significant differences in the distribution of the two p53 isoforms between the patients with skin cancer and the control population. The predominant viral types detected in both the patients and the control group were EV associated HPVs, although the incidence was lower in normal skin samples than in malignant lesions or viral warts. Conclusions-These results suggest that in a Celtic population there is no correlation between the presence of HPV, the p53 codon 72 arginine polymorphism, and the development of skin cancer.

Original languageEnglish
Pages (from-to)539-542
Number of pages4
JournalJournal of Clinical Pathology
Volume54
Issue number7
DOIs
Publication statusPublished - 2001

Fingerprint

Skin Neoplasms
Codon
Arginine
Proline
Skin
Volunteers
Squamous Cell Carcinoma
Genotype
Population
Warts
Papillomavirus Infections
Tumor Suppressor Genes
Protein Isoforms
Kidney
Polymerase Chain Reaction
Control Groups
Incidence
Neoplasms
Proteins

Keywords

  • Human papillomavirus
  • p53 codon 72 polymorphism
  • Skin cancer

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

p53 codon 72 polymorphism and human papillomavirus associated skin cancer. / O'Connor, D. P.; Kay, E. W.; Leader, M.; Atkins, G. J.; Murphy, G. M.; Mabruk, M. J E M F.

In: Journal of Clinical Pathology, Vol. 54, No. 7, 2001, p. 539-542.

Research output: Contribution to journalArticle

O'Connor, DP, Kay, EW, Leader, M, Atkins, GJ, Murphy, GM & Mabruk, MJEMF 2001, 'p53 codon 72 polymorphism and human papillomavirus associated skin cancer', Journal of Clinical Pathology, vol. 54, no. 7, pp. 539-542. https://doi.org/10.1136/jcp.54.7.539
O'Connor, D. P. ; Kay, E. W. ; Leader, M. ; Atkins, G. J. ; Murphy, G. M. ; Mabruk, M. J E M F. / p53 codon 72 polymorphism and human papillomavirus associated skin cancer. In: Journal of Clinical Pathology. 2001 ; Vol. 54, No. 7. pp. 539-542.
@article{1e00657beecb450086f77edbd35c60db,
title = "p53 codon 72 polymorphism and human papillomavirus associated skin cancer",
abstract = "Background/Aims-Non-melanoma skin cancers frequently harbour multiple human papillomavirus (HPV) types. A recent report suggests that a polymorphism of the p53 tumour suppressor gene that results in the substitution of a proline residue with an arginine residue at position 72 of the p53 protein might act as a risk factor in HPV associated malignancies. This study aimed to determine the following: (1) the relation between HPV infection and the development of cutaneous squamous cell carcinoma (SCC), and (2) whether there is a correlation between p53 codon 72 polymorphism and the development of SCC. Methods-Blood samples were taken from 55 patients with skin cancer (both renal transplant recipients and immunocompetent patients with skin cancer) and 115 ethnically matched volunteers. A polymerase chain reaction based assay was used to determine p53 codon 72 genotypes. In addition, 49 benign and malignant lesions from 34 of the patients with skin cancer and 20 normal human skin samples from 20 of the control volunteers were examined for HPV. Results-The proportions of p53 codon 72 genotypes found were 78{\%} arginine homozygous, 2{\%} proline homozygous, and 20{\%} heterozygous among patients with skin cancer and 79{\%} arginine homozygous, 3.5{\%} proline homozygous, and 17.5{\%} heterozygous among the control population. Statistical analysis showed no significant differences in the distribution of the two p53 isoforms between the patients with skin cancer and the control population. The predominant viral types detected in both the patients and the control group were EV associated HPVs, although the incidence was lower in normal skin samples than in malignant lesions or viral warts. Conclusions-These results suggest that in a Celtic population there is no correlation between the presence of HPV, the p53 codon 72 arginine polymorphism, and the development of skin cancer.",
keywords = "Human papillomavirus, p53 codon 72 polymorphism, Skin cancer",
author = "O'Connor, {D. P.} and Kay, {E. W.} and M. Leader and Atkins, {G. J.} and Murphy, {G. M.} and Mabruk, {M. J E M F}",
year = "2001",
doi = "10.1136/jcp.54.7.539",
language = "English",
volume = "54",
pages = "539--542",
journal = "Journal of Clinical Pathology - Clinical Molecular Pathology",
issn = "0021-9746",
publisher = "BMJ Publishing Group",
number = "7",

}

TY - JOUR

T1 - p53 codon 72 polymorphism and human papillomavirus associated skin cancer

AU - O'Connor, D. P.

AU - Kay, E. W.

AU - Leader, M.

AU - Atkins, G. J.

AU - Murphy, G. M.

AU - Mabruk, M. J E M F

PY - 2001

Y1 - 2001

N2 - Background/Aims-Non-melanoma skin cancers frequently harbour multiple human papillomavirus (HPV) types. A recent report suggests that a polymorphism of the p53 tumour suppressor gene that results in the substitution of a proline residue with an arginine residue at position 72 of the p53 protein might act as a risk factor in HPV associated malignancies. This study aimed to determine the following: (1) the relation between HPV infection and the development of cutaneous squamous cell carcinoma (SCC), and (2) whether there is a correlation between p53 codon 72 polymorphism and the development of SCC. Methods-Blood samples were taken from 55 patients with skin cancer (both renal transplant recipients and immunocompetent patients with skin cancer) and 115 ethnically matched volunteers. A polymerase chain reaction based assay was used to determine p53 codon 72 genotypes. In addition, 49 benign and malignant lesions from 34 of the patients with skin cancer and 20 normal human skin samples from 20 of the control volunteers were examined for HPV. Results-The proportions of p53 codon 72 genotypes found were 78% arginine homozygous, 2% proline homozygous, and 20% heterozygous among patients with skin cancer and 79% arginine homozygous, 3.5% proline homozygous, and 17.5% heterozygous among the control population. Statistical analysis showed no significant differences in the distribution of the two p53 isoforms between the patients with skin cancer and the control population. The predominant viral types detected in both the patients and the control group were EV associated HPVs, although the incidence was lower in normal skin samples than in malignant lesions or viral warts. Conclusions-These results suggest that in a Celtic population there is no correlation between the presence of HPV, the p53 codon 72 arginine polymorphism, and the development of skin cancer.

AB - Background/Aims-Non-melanoma skin cancers frequently harbour multiple human papillomavirus (HPV) types. A recent report suggests that a polymorphism of the p53 tumour suppressor gene that results in the substitution of a proline residue with an arginine residue at position 72 of the p53 protein might act as a risk factor in HPV associated malignancies. This study aimed to determine the following: (1) the relation between HPV infection and the development of cutaneous squamous cell carcinoma (SCC), and (2) whether there is a correlation between p53 codon 72 polymorphism and the development of SCC. Methods-Blood samples were taken from 55 patients with skin cancer (both renal transplant recipients and immunocompetent patients with skin cancer) and 115 ethnically matched volunteers. A polymerase chain reaction based assay was used to determine p53 codon 72 genotypes. In addition, 49 benign and malignant lesions from 34 of the patients with skin cancer and 20 normal human skin samples from 20 of the control volunteers were examined for HPV. Results-The proportions of p53 codon 72 genotypes found were 78% arginine homozygous, 2% proline homozygous, and 20% heterozygous among patients with skin cancer and 79% arginine homozygous, 3.5% proline homozygous, and 17.5% heterozygous among the control population. Statistical analysis showed no significant differences in the distribution of the two p53 isoforms between the patients with skin cancer and the control population. The predominant viral types detected in both the patients and the control group were EV associated HPVs, although the incidence was lower in normal skin samples than in malignant lesions or viral warts. Conclusions-These results suggest that in a Celtic population there is no correlation between the presence of HPV, the p53 codon 72 arginine polymorphism, and the development of skin cancer.

KW - Human papillomavirus

KW - p53 codon 72 polymorphism

KW - Skin cancer

UR - http://www.scopus.com/inward/record.url?scp=0034946190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034946190&partnerID=8YFLogxK

U2 - 10.1136/jcp.54.7.539

DO - 10.1136/jcp.54.7.539

M3 - Article

VL - 54

SP - 539

EP - 542

JO - Journal of Clinical Pathology - Clinical Molecular Pathology

JF - Journal of Clinical Pathology - Clinical Molecular Pathology

SN - 0021-9746

IS - 7

ER -